Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo was a late entrant in the saturated checkpoint inhibitor market and sales to date have been negligible but more promising late-stage data evaluating the drug in cervical cancer suggests the partners could carve out a lucrative niche in that less competitive indication.
Regeneron and Sanofi have presented updated results from the 304-patient Phase III trial investigating Libtayo (cemiplimab) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?